Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 17/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16558740 | 0.85 | METAP1 (0.39) | P2RX7METAP1CYP19A1SSTR4 | |
| SCHEMBL16552796 | 0.83 | CYP19A1 (0.44) | P2RX7METAP1CYP19A1 | |
| SCHEMBL16558741 | 0.81 | HTR1A (0.38) | P2RX7CYP19A1SSTR4 | |
| SCHEMBL16558737 | 0.78 | CYP19A1 (0.37) | P2RX7METAP1CYP19A1SSTR4 | |
| SCHEMBL16558745 | 0.77 | CYP19A1 (0.43) | P2RX7METAP1CYP19A1SSTR4 | |
| SCHEMBL16552907 | 0.76 | ACHE (0.46) | METAP1CYP19A1 | |
| SCHEMBL16558734 | 0.72 | CYP19A1 (0.37) | CYP19A1 | |
| SCHEMBL16558744 | 0.71 | ACHE (0.38) | — | |
| SCHEMBL16552693 | 0.70 | CYP19A1 (0.58) | METAP1CYP19A1 | |
| SCHEMBL16552897 | 0.70 | PDE4D (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446047-B2 | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160213627-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-9359315-B2 | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150072980-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213627-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | P2RX7 1786/4885METAP1 3605/4885CYP19A1 246/4885 |
| US-20150072980-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | P2RX7 1786/4885METAP1 3605/4885CYP19A1 246/4885 |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | P2RX7 1786/4885METAP1 3605/4885CYP19A1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.